Journals / Literatür Eczacılık Bilimleri Dergisi / 2018 / Cilt: 7 - Sayı: 1

Bisphosphonates Used in the Treatment of Osteoporosis and Their Toxicities

Osteoporoz Tedavisinde Kullanılan Bifosfonat Grubu İlaçlar ve Toksisiteleri

Pages
35–48
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this review article is summarized definition of osteoporosis, pathophysiology of osteoporosis and osteoporosis treatment, within these the effect mechanisms, physicochemichal proporties, pharmacokinetics, toxicities of biphosphonates and informations about drugs entering this class.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Osteoporosis, is an important health problem that cause morbidity and mortality, is also common in our country.
📊
Key Findings & Data:In particular, there is an increase in the incidence of the disease with age, but there are also differences depending on the sex.
💡
Conclusion & Impact:In this review article is summarized definition of osteoporosis, pathophysiology of osteoporosis and osteoporosis treatment, within these the effect mechanisms, physicochemichal proporties, pharmacokinetics, toxicities of biphosphonates and informations about drugs entering this class.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Osteoporosis, is an important health problem that cause morbidity and mortality, is also common in our country. In particular, there is an increase in the incidence of the disease with age, but there are also differences depending on the sex. Various drug groups are used in the treatment of osteoporosis. These drugs are divided into two classes as antiresorptive drugs and anabolic agents. Among these, biphosphonates are drugs that commonly are used and inhibit bone resorption. Biphosphonates have a high affinity for bone mineral. They do not metabolize in the body and interact with other medicines. Oral biphosphonates treatment cause toxicities such as oesophageal ulcers, oesophagitis, and hemorrhages. Renal toxicity, acute phase reactions, jaw osteonecrosis, atrial fibrillation, atypical fractures and ocular adverse reactions have been observed as for result of the long-term use of intravenous biphosphonates. In this review article is summarized definition of osteoporosis, pathophysiology of osteoporosis and osteoporosis treatment, within these the effect mechanisms, physicochemichal proporties, pharmacokinetics, toxicities of biphosphonates and informations about drugs entering this class.

Özet

Osteoporoz, ülkemizde de yaygın olarak görülen, morbidite ve mortaliteye neden olan önemli bir sağlık sorunudur. Özellikle, yaşla birlikte hastalığın insidansında artış gözlenmekle birlikte, cinsiyete bağlı olarak da çeşitli farklılıklar bulunmaktadır. Osteoporoz tedavisinde çeşitli ilaç grupları kullanılmaktadır. Bu ilaçlar, yıkımı önleyici ilaçlar ve anabolik ajanlar olmak üzere iki sınıfa ayrılmaktadır. Bunlar içinde bifosfonatlar, sıklıkla kullanılan ve kemik yıkımını inhibe eden ilaçlardandır. Bifosfonatların kemik mineraline afinitesi yüksektir. Vücutta metabolize olmazlar ve diğer ilaçlarla etkileşime girmezler. Oral bifosfonat tedavisi, özofagus ülserleri, özofajit ve kanamalar gibi toksisitelere neden olmaktadır. Uzun süreli intravenöz bifosfonat kullanımı sonucu ise böbrek toksisitesi, akut faz reaksiyonları, çene osteonekrozu, atriyal fibrilasyon, atipik kırıklar ve oküler advers reaksiyonlar gözlenmiştir. Bu çalışmada; osteoporozun tanımı, patofizyolojisi ve osteoporoz tedavisi ve bunlar içinde bifosfonatların etki mekanizmaları, fizikokimyasal özellikleri, farmakokinetikleri, toksisiteleri ve bu sınıfa giren ilaçlar ile ilgili bilgiler özetlenmiştir.

🔖

Cite This Article

DİNÇEL, S., SABUNCUOĞLU, S. (2018). Bisphosphonates Used in the Treatment of Osteoporosis and Their Toxicities. Literatür Eczacılık Bilimleri Dergisi, Cilt: 7 - Sayı: 1, 35–48. https://ajindex.com/articles/274579

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (17)

  1. World Health Organization (WHO). Prevention and management of osteoporosis. Rapor No: 921. Geneva: WHO Press; 2003. p.165
  2. Lewiecki EM. Bisphosphonates for the treatment of osteoporosis: insight for clinicians. Ther Adv Chronic Dis 2010;1(3):115-28
  3. Szulc P, Bouxsein ML. Vertebral Fracture Initiative Part I Overview of Osteoporosis: Epidemiology and Clinical Management. UK: Department of Medicine, Addenbrooke’s Hospital, Cambridge University; 2016. p.66
  4. Gulsahi A. Osteoporosis and jawbones in women. J Int Soc Prev Community Dent 2015;5(4):263-7
  5. McCombs JS, Thiebaud P, McLaughlin-Miley C, Shi J. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 2004;48(3):271-87
  6. Kanis JA, Delmas P, Burckhardt P, Cooper C, Torgerson D. Guidelines for diagnosis and management of osteoporosis. The European Foundation for Osteoporosis and Bone Disease. Osteoporos Int 1997;7(4):390- 406
  7. Lewiecki EM. Management of osteoporosis. Clin Mol Allergy 2004;2(1):9
  8. Vondracek SF, Minne P, McDermott MT. Clinical challenges in the management of osteoporosis. Clin Interv Aging 2008;3(2):315-29
  9. Kanis JA, McCloskey EV, Harvey NC, Johansson H, Leslie WD. Intervention thresholds and the diagnosis of osteoporosis. J Bone Miner Res 2015;30(10):1747-53
  10. Klein-Nulend J, van Oers RF, Bakker AD, Bacabac RG. Bone cell mechanosensitivity, estrogen deficiency, and osteoporosis. J Biomech 2015;48(5):855-65
  11. Rossini M, Adami S, Bertoldo F, Diacinti D, Gatti D, Giannini S, et al. Guidelines for the diagnosis, prevention and management of osteoporosis. Reumatismo 2016;68(1):1-39
  12. Akbal A, Gökmen F, Gencer M, Inceer BS, Kömürcü E. Mean platelet volume and platelet distribution width can be related to bone mineralization. Osteoporos Int 2014;25(9):2291- 5
  13. Tomlinson BD, Prater GL, Morgan SL. Osteoporosis and imaging: the big picture. J Radiol Nurs 2016;35(2):97-110
  14. Lewiecki EM. Fracture risk assessment in clinical practice: T-scores, FRAX, and beyond. Clinic Rev Bone Miner Metab 2010;8(3):101- 12
  15. Cosman F, de Beur SJ, LeBoff MS, Lewiecki EM, Tanner B, Randall S, et al. Clinician’s guide to prevention and treatment of osteoporosis. Osteoporos Int 2014;25(10):2359- 81
  16. Dallanezi G, Freire BF, Nahás EA, NahásNeto J, Corrente JE, Mazeto GM. Physical activity level of post-menopausal women with low bone mineral density. Rev Bras Ginecol Obstet 2016;38(5):225-30
  17. Angin E, Erden Z. [The effect of group exercise